Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.45 |
| ▸ | MTOR | P42345 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246130 | 0.86 | LRRK2 (0.50) | CYP2C19PIK3CAMTORPDE10ALRRK2 | |
| SCHEMBL246984 | 0.85 | CYP2C19 (0.52) | CYP2C19PIK3CAMTORPDE10ALRRK2 | |
| SCHEMBL248167 | 0.81 | PIK3CA (0.46) | CYP2C19PIK3CAMTORALDH1A1CYP1A2 | |
| SCHEMBL5564075 | 0.80 | CYP2C19 (0.54) | CYP2C19PIK3CAMTORALDH1A1CYP1A2 | |
| SCHEMBL248166 | 0.79 | ATR (0.49) | CYP2C19PIK3CAMTORPDE10ALRRK2 | |
| SCHEMBL24921465 | 0.76 | CYP2C19 (0.59) | CYP2C19ALDH1A1CYP1A2MAPTCYP2C9 | |
| SCHEMBL246958 | 0.76 | ALK (0.49) | PIK3CAMTORPDE10ALRRK2ALK | |
| SCHEMBL15543262 | 0.76 | ALDH1A1 (0.48) | CYP2C19PIK3CAMTORALDH1A1CYP1A2 | |
| SCHEMBL29745217 | 0.76 | ALDH1A1 (0.48) | CYP2C19PIK3CAMTORALDH1A1CYP1A2 | |
| SCHEMBL24920399 | 0.75 | CYP2C19 (1.00) | CYP2C19ALDH1A1CYP1A2CYP2C9PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | CYP2C19 1555/4885PIK3CA 28/4885MTOR 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.